News FDA approves first ALS treatment for two decades FDA asked Mitsubishi to file Radicava following approval in Japan.
News Biotech IPO market heats up as BioHaven's debut impresses BioHaven raises $168 million with biggest biotech IPO seen this year.
Views & Analysis Ultra-rare disease drugs: has access in England just got har... Gaining access to ultra-orphan drugs could become much more difficult.
Views & Analysis Getting a rarer perspective Benefitting from insights from focus groups with rare disease patients.
News Biogen shares up after strong launch for rare disease drug US insurers are covering the treatment, despite high price.
News EU regulators back two more orphan drugs, question of pricin... Two orphan medicines are heading towards the European market, after regulators recommended rare disease drugs from Biogen and BioMarin.
News Kelun's MSD-partnered TROP2 drug gets first okay in China Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
